UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: PR Newswire
ATLANTA, Oct. 29, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the opening of applications for the second annual UCB U.S. Myasthenia Gravis Scholarship™, supporting individuals impacted by myasthenia gravis (MG) including patients, caregivers, and family members who are pursuing further education. To learn more the UCB Myasthenia Gravis Scholarship, or to apply online, visit www.UCBMGscholarship.com. In 2026, UCB will again award 15 scholarships. This year's application deadline is January 31, 2026. "The UCB U.S. Myasthenia Gravis Scholarship™ is dedicated to supporting people impacted by myasthenia gravis," said Kimberly Moran, PhD, MBA, SVP & Head, US Rare Diseases. "It's one of the many ways UCB is committed to empowering patients and caregivers—beyond medicine—through meaningful resources that help them thrive." In the program's inaugural year, UCB helped recipients pursue diverse edu
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB shares leading scientific research and advances at American Epilepsy Society Annual MeetingPR Newswire
- UCB (OTCMKTS:UCBJY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)PR Newswire
- UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific SessionPR Newswire
- UCB (OTCMKTS:UCBJY) was upgraded by analysts at Jefferies Financial Group Inc. to a "moderate sell" rating.MarketBeat